140410.KQ KOE
Mezzion Pharma Co.,Ltd.
1W: -17.3%
1M: +2.3%
3M: +10.4%
YTD: -55.2%
1Y: +84.5%
3Y: +61.7%
5Y: +51.0%
₩68,000.00 ($50.69)
-5600.00 (-7.61%)
Weekly Expected Move ±9.2%
₩55487
₩61743
₩68000
₩74257
₩80513
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$7.9B
-8.2% ▼
5Y CAGR: -22.7%
Gross Profit
$464M
-75.7% ▼
5Y CAGR: -42.6%
Operating Income
-$16.8B
-17.3% ▼
Net Income
-$34.9B
-79.3% ▼
EPS (Diluted)
$-1150.34
-75.6% ▼
EBITDA
-$15.8B
-18.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.7B | $30.7B | $31.7B | $8.6B | $7.9B |
| YoY Growth | -6.9% | +15.3% | +3.2% | -72.9% | -8.2% |
| Cost of Revenue | $23.0B | $31.0B | $27.8B | $6.7B | $7.4B |
| Gross Profit | $3.7B | -$313M | $3.9B | $1.9B | $464M |
| Gross Margin | 13.9% | -1.0% | 12.2% | 22.2% | 5.9% |
| R&D Expenses | $2.0B | $2.2B | $939M | $294M | $0 |
| SG&A Expenses | $10.2B | $10.9B | $9.4B | $10.2B | $0 |
| Operating Expenses | $20.5B | $23.0B | $18.4B | $16.2B | $17.2B |
| Operating Income | -$16.8B | -$23.3B | -$14.5B | -$14.3B | -$16.8B |
| Operating Margin | -63.0% | -75.9% | -45.7% | -166.0% | -212.0% |
| Interest Expense | $323M | $423M | $165M | $301M | $1.6B |
| Income Before Tax | -$13.0B | -$35.9B | -$12.5B | -$14.5B | -$38.8B |
| Tax Expense | $577M | $388M | $248M | $4.9B | -$3.9B |
| Net Income | -$13.6B | -$36.3B | -$12.7B | -$19.5B | -$34.9B |
| Net Margin | -51.0% | -118.1% | -40.1% | -226.2% | -441.6% |
| EPS (Diluted) | $-509.70 | $-1358.00 | $-451.00 | $-655.11 | $-1150.34 |
| EBITDA | -$15.2B | -$21.7B | -$10.6B | -$13.3B | -$15.8B |
| Shares Outstanding | 27M | 27M | 28M | 30M | 30M |